Sanofi - American Depositary Shares (NQ:SNY)

39.72 -0.20 (-0.51%)

Delayed Quote Updated: 3:41 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2

...

20 21 22 23 24 25 26 27 28

...

42 43 Next >

Exscientia is the Sniper of the AI Drug Discovery Industry

July 27, 2023

News of a $50 million investment by artificial intelligence (AI) leader Nvidia Co. (Nasdaq: NVDA) into AI-powered drug discovery company Recursion

Via MarketBeat

Topics Artificial Intelligence

Novo Nordisk's Diabetes, Weight Loss Drugs Under UK Scrutiny: Follows Suicidal Behavior Reports ↗

July 26, 2023

The Medicines and Healthcare Products Regulatory Agency (MHRA), the U.K.'s drug regulatory authority, is reportedly scrutinizing a category of drugs used in diabetes medication and a weight loss...

Via Benzinga

7 Blue-Chip Stocks That Are Screaming Buys Right Now: July 2023 ↗

July 23, 2023

Even some of the top players of the market don’t get the attention they deserve, making these blue-chip stocks compelling.

Via InvestorPlace

How Is The Market Feeling About Sanofi? ↗

July 20, 2023

Via Benzinga

Looking Into Sanofi's Recent Short Interest ↗

July 03, 2023

Via Benzinga

2 Biopharma Stocks Making Big Moves Tuesday ↗

June 20, 2023

Markets looked poised for a pause, but these stocks didn't stand still.

Via The Motley Fool

2 Best Biotech Stocks to Buy Right Now ↗

June 16, 2023

These international-based pharmaceutical companies pay market-topping dividends to shareholders.

Via The Motley Fool

Recludix Pharma Enters into a Strategic Collaboration with Sanofi to Advance Novel Oral STAT6 Inhibitor in Multiple Immunological and Inflammatory Indications

July 20, 2023

From Recludix Pharma, Inc.

Via GlobeNewswire

NBCUniversal's Peacock Raises Prices First Time Since Launch, Warren Buffett Sells Majority of Activision Blizzard Stake Before Microsoft Deal Approval, Novartis Launches $15B Share Buyback: Today's Top Stories ↗

July 18, 2023

Wall Street Journal

Via Benzinga

AstraZeneca-Sanofi's Respiratory Syncytial Virus Treatment Scores FDA Approval To Prevent Infection In Infants ↗

July 18, 2023

The FDA approved AstraZeneca Plc (NASDAQ:

Via Benzinga

Phase 1 Results Are "Extraordinary," Says Chairman Of Scientific Advisory Board As Biomedical Company Preps Phase 2 Trial For MS Treatment ↗

July 17, 2023

Tiziana Life Sciences (NASDAQ: TSLA) has presented data from its clinical trial showing that five of its six patients with an advanced stage of multiple sclerosis (MS) have shown a reduction in...

Via Benzinga

Is Affordable Insulin Available? Survey Reveals Uninsured Americans Paying More Despite Promised Price Reduction ↗

July 13, 2023

According to a survey conducted by U.S.

Via Benzinga

Why Shares of Exscientia Jumped on Wednesday ↗

July 12, 2023

The company may be riding the wave of an AI healthcare boom.

Via The Motley Fool

Takeda Withdraws FDA Application For Dengue Vaccine Candidate On Data Disagreement ↗

July 12, 2023

Takeda Pharmaceutical Co Ltd (NYSE: TAK) said on Tuesday that it was voluntarily

Via Benzinga

Publications And Positive Data From Multiple Trials: Six Months In Review For Tiziana Life Sciences (NASDAQ: TLSA) ↗

July 10, 2023

Tiziana Life Sciences (NASDAQ: TLSA) is a biotechnology company establishing itself in a cutting-edge position in the market with its breakt

Via Benzinga

Evotec Secures US Government Contract For Orthopoxvirus Antibody ↗

July 05, 2023

The U.S.

Via Benzinga

First US Trial Over Zantac's Alleged Cancer-Causing Properties Set For November In California ↗

July 03, 2023

The initial U.S. court trial concerning the antacid medication Zantac is slated to commence on November 13 in a state court in California, as stated by a lawyer representing the plaintiffs.

Via Benzinga

Sanofi's Amlitelimab Hits Primary Goal In Mid-Stage Atopic Dermatitis Study ↗

June 27, 2023

Sanofi SA (NASDAQ: SNY) says its Phase 2b study (STREAM-AD) of amlitelimab for adults with moderate-to-severe atopic dermatitis, who cannot adequately manage their condition with topical medications,...

Via Benzinga

AI Stocks: C3.ai, Palantir Pull Back Amid HPE, Cybersecurity, Cloud AI News ↗

June 23, 2023

The big rally in AI stocks may finally be taking a break but the steady drumbeat in artificial intelligence news continues.

Via Investor's Business Daily

GSK Confidentially Settles First Zantac-Associated Cancer Lawsuit Due For US Trial Next Month ↗

June 23, 2023

GSK plc (NYSE: GSK) has reached a confidential settlement with James Goet

Via Benzinga

European Drug Authority Raises Thyroid Cancer Safety Signal For Novo Nordisk Drugs, Including Hyped Semaglutide ↗

June 22, 2023

The EU's drugs watchdog, the European Medicines Agency, recently raised a thyroid cancer safety signal for Novo Nordisk A/S (NYSE: NVO) drugs, including the much talked semaglutide used i

Via Benzinga

Spotify to Launch New Expensive Subscription Plan, Chinese Vendors Bypass US Embargo to Supply Nvidia AI Chips, Eddie Wu To Succeed Daniel Zhang As Alibaba's CEO: Today's Top Stories ↗

June 20, 2023

Bloomberg

Via Benzinga

Sanofi Stock Is Trading Higher Today - Here's Why ↗

June 20, 2023

Sanofi SA (NASDAQ: SNY) announced that the tribunal dismissed Boehringer Ingelheim's indemnification claim against Sanofi in an International Chamber of Commerce dispute in cancer lawsuits linked to...

Via Benzinga

Tiziana Life Sciences (NASDAQ: TLSA) Announces Positive Data In Its Secondary-Progressive Multiple Sclerosis Trial, What Could This Mean For The Company? ↗

June 15, 2023

Company Moves Ahead With Drug Development

Via Benzinga

DarioHealth is an AI-Powered Digital Therapeutics Play

June 13, 2023

DarioHealth Co. (NASDAQ: DRIO) is an AI-powered digital therapeutics platform and provider that adaptively personalizes monitoring and treatments for chronic

Via MarketBeat

Topics Artificial Intelligence

Netflix Gains Subs From Password Sharing Crackdown, Mark Zuckerberg Discusses AI at Latest Employee Met, Privacy Breach Risk in Nvidia's AI Technology Stirs Concern: Today's Top Stories ↗

June 09, 2023

Financial Times

Via Benzinga

Unanimous Support for AstraZeneca and Sanofi's Nirsevimab: Next Generation RSV Treatment on the Horizon ↗

June 09, 2023

The FDA's Antimicrobial Drugs Advisory Committee has voted unanimously 21 to 0 that AstraZeneca plc (NASDAQ: AZN) and Sanofi SA's (NASDAQ: SNY) nirsevimab has a favorable benefit-risk profile t

Via Benzinga

Why Shares of Innate Pharma Jumped Thursday ↗

June 08, 2023

The company's collaboration agreement with Sanofi could soon pay off.

Via The Motley Fool

The 7 Most Reliable Dividend Stocks to Buy Now ↗

June 06, 2023

Faced with a tricky market backdrop, investors may take significant comfort with the most reliable dividend stocks to buy.

Via InvestorPlace

The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree ↗

June 02, 2023

Big Pharma is facing a patent cliff that could siphon off billions in revenue.

Via Investor's Business Daily

< Previous 1 2

...

20 21 22 23 24 25 26 27 28

...

42 43 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.